Form 4: LIFECORE BIOMEDICAL Director and 10% Owner Sells Over 1.3 Million Shares

Aron R. English, a Director and 10% owner of LIFECORE BIOMEDICAL, INC., along with affiliated entities, reported the sale of over 1.3 million shares of common stock across multiple transactions in late May 2025.

Summary

• Aron R. English, a Director and 10% owner of LIFECORE BIOMEDICAL, INC. (LFCR), and associated entities including 22NW Fund, LP, 22NW, LP, 22NW Fund GP, LLC, and 22NW GP, Inc., collectively reported significant sales of common stock.
• On May 23, 2025, 96,137 shares were sold at a weighted average price of $6.7548 per share, with prices ranging from $6.7500 to $6.7800.
• On May 27, 2025, a substantial 1,139,504 shares were disposed of at a weighted average price of $6.5042 per share, with prices ranging from $6.500 to $6.900.
• On May 28, 2025, an additional 150,419 shares were sold at a weighted average price of $7.1238 per share, with prices ranging from $6.9000 to $7.5000.
• The total number of shares sold across these three transactions amounts to 1,386,060 shares.
• Following these transactions, the indirect beneficial ownership by 22NW Fund, LP, decreased to 264,180 shares as of May 28, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a director and 10% owner, which typically signals a lack of confidence or a belief that the stock is fully valued or overvalued.

Negatives

• A significant volume of shares (1,386,060) were sold by a Director and 10% owner, which can be interpreted as a lack of confidence in the company's near-term prospects.
• The sales occurred over several days, indicating a sustained divestment rather than a one-off event.

Risks

• The substantial insider selling by a director and major shareholder could signal potential concerns about the company's future performance or valuation, leading to negative market sentiment.
• Increased selling pressure on the stock due to the large volume of shares offloaded by a significant holder.

Future Outlook

The document does not contain any explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Aron R. English, as Portfolio Manager of 22NW, Manager of 22NW GP, and President and sole shareholder of 22NW Inc., along with the other Reporting Persons, disclaims beneficial ownership of the securities reported except to the extent of his or its pecuniary interest therein.
• The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the reported ranges.

Industry Context

Insider selling, particularly by a director and significant shareholder, is often closely watched by the market as it can be perceived as a signal regarding the insider's view of the company's future prospects or valuation. While not uncommon, large-scale divestment can sometimes precede periods of underperformance relative to industry peers.

Comparison to Industry Standards

• Insider selling is a common occurrence across all industries, but the scale and consistency of sales by a director and 10% owner like Aron R. English and 22NW Fund, LP, for LIFECORE BIOMEDICAL (LFCR) are notable.
• Compared to typical insider transactions, the sale of over 1.3 million shares represents a significant reduction in the beneficial ownership of a key insider group, which could be viewed more negatively than routine sales for liquidity or diversification.

Related Party Transactions

• The reported sales of common stock by Aron R. English and the affiliated 22NW entities constitute related party transactions, as Mr. English is a Director and the entities are 10% owners of LIFECORE BIOMEDICAL, INC.

Stakeholder Impact

• Shareholders may interpret the significant insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Potential impact on market perception of the company's valuation and future growth prospects.

Next Steps

• The Reporting Persons undertake to provide detailed information on specific share prices within the reported ranges upon request from the Issuer, security holders, or the SEC.

Key Dates

Recommendation

Keywords

LIFECORE BIOMEDICAL, LFCR, Insider Selling, Form 4, Aron R. English, 22NW Fund, Stock Sales, Beneficial Ownership, SEC Filing, Director Sales, 10% Owner